The writing has been on the wall for years: the shift away from fee for service to value-based pay is coming. Recently that message, now in bold type, proliferated to every healthcare media outlet ...

Ray Therapeutics’ gene therapy is independent of the causative genes driving inherited vision disorders, which CEO Paul Bresge says is important for reaching a broad patient population.